Carmine De Angelis, MD, PhD
Carmine De Angelis, MD, PhD
University of Naples "Federico II", Naples (Italy) - Baylor College of Medicine, Houston (Texas)
Verified email at
Cited by
Cited by
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
TY Kim, GM Kim, M Martín, C Zielinski, M Ruíz-borrego, E Carrasco, ...
Journal of Clinical Oncology, 32-45, 2019
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff
Nature reviews Clinical oncology 12 (10), 573, 2015
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ...
Breast cancer research and treatment 136 (3), 795-804, 2012
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ...
Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016
The changing role of ER in endocrine resistance
A Nardone, C De Angelis, MV Trivedi, CK Osborne, R Schiff
The Breast 24, S60-S66, 2015
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer
G Arpino, C De Angelis, M Giuliano, A Giordano, C Falato, ...
Oncology 77 (Suppl. 1), 23-37, 2009
The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer
R Jeselsohn, C De Angelis, M Brown, R Schiff
Current oncology reports 19 (5), 35, 2017
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy
M Giuliano, H Hu, YC Wang, X Fu, A Nardone, S Herrera, S Mao, ...
Clinical Cancer Research 21 (17), 3995-4003, 2015
HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer
X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ...
Clinical Cancer Research 23 (17), 5123-5134, 2017
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
R Jeselsohn, MI Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, ...
Proceedings of the National Academy of Sciences 114 (22), E4482-E4491, 2017
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis
Y Wu, Z Zhang, ME Cenciarini, CJ Proietti, M Amasino, T Hong, M Yang, ...
Cancer research 78 (3), 671-684, 2018
Overcoming Treatment Resistance in HER2-Positive Breast Cancer
F Puglisi, AM Minisini, C De Angelis, G Arpino
Drugs 72 (9), 1175-1193, 2012
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
MF Rimawi, C De Angelis, A Contreras, F Pareja, FC Geyer, KA Burke, ...
Breast cancer research and treatment 167 (3), 731-740, 2018
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis
M Bonotto, L Gerratana, M Di Maio, C De Angelis, M Cinausero, S Moroso, ...
The Breast 31, 114-120, 2017
Towards personalized treatment for early stage HER2-positive breast cancer
K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ...
Nature Reviews Clinical Oncology 17 (4), 233-250, 2020
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ...
JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance
J Veeraraghavan, C De Angelis, JS Reis-Filho, T Pascual, A Prat, ...
The Breast 34, S19-S26, 2017
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ...
The lancet oncology 19 (4), 474-485, 2018
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
G Arpino, C De Angelis, G Buono, A Colao, M Giuliano, S Malgieri, ...
Breast cancer research and treatment 154 (1), 127-132, 2015
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ...
Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019
The system can't perform the operation now. Try again later.
Articles 1–20